论文部分内容阅读
目的:观察沙利度胺(反应停)联合化疗治疗多发性骨髓瘤(MM)的临床疗效和不良反应。方法:13例MM患者分成2组,对照组用VAD方案化疗,治疗组在VAD方案上加用沙利度胺,治疗6个疗程,根据血清M蛋白、骨髓瘤细胞减少等指标判断疗效。结果:总有效率治疗组85.7%,对照组50.0%,两组间差异有显著性(P<0.05)。治疗组中便秘、腹胀和水肿增加,经对症处理后较快消失,其他不良反应与对照组相同。结论:沙利度胺联合VAD方案化疗治疗MM具有疗效明显增加,耐受性良好的优点。
Objective: To observe the clinical efficacy and adverse reactions of thalidomide (reaction stop) combined with chemotherapy in the treatment of multiple myeloma (MM). Methods: Thirteen patients with MM were divided into two groups. The control group was treated with VAD regimen. The treatment group was treated with thalidomide on the VAD regimen for 6 courses. The efficacy was judged based on serum M protein and myeloma cell reduction. Results: The total effective rate was 85.7% in the treatment group and 50.0% in the control group. There was a significant difference between the two groups (P<0.05). Constipation, bloating, and edema increased in the treatment group and disappeared quickly after symptomatic treatment. Other adverse reactions were the same as in the control group. Conclusion: Thalidomide combined with VAD regimen chemotherapy has a significant increase in efficacy and good tolerability.